Chronic Kidney DiseaseNCT07481526
A Prospecitve Multicenter, Observational Registry Study
An observational study of Chronic Kidney Disease, run by AstraZeneca at 59 sites in China.
Trial summary
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Chronic Kidney Disease
- How many people
- 3,000 participants
- Where
- 59 sitesChina
- Study dates
- 27 Feb 2026to 30 Dec 2028
- How long will I take part?
- 96 Weeks
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adult CKD patients who meet the eligibility criteria
Who may be able to join
- Male or female patients aged ≥18 years.
- Willing and able to provide written informed consent to participate in the study.
- Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
- eGFR <60 mL/min/1.73 m² for ≥3 months, OR
- Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months
Who cannot join
- Having a life-threatening comorbidity with life expectancy < 2 years.
- Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
- Pregnant or breastfeeding women.
- Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
- Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
Trial locations and contacts
59 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
59 sites in 1 country
China59 sites, 59 recruiting
- Recruiting
Research Site
Anning, Yunnan - South Region
- Recruiting
Research Site
Beijing, Beijing
- Recruiting
Research Site
Cangzhou, Hebei - North Region
- Recruiting
Research Site
Caoxian County, Shandong Province
- Recruiting
Research Site
Changzhou, Jiangsu Province
- Recruiting
Research Site
Chengdu, Sichuan Province
- Recruiting
Research Site
Chongqing, Chongqing
- Recruiting
Research Site
Chongqing, Sichuan Province
- Not yet recruiting
Research Site
Dalian, Liaoning
- Recruiting
Research Site
Dongguan, Guangdong
- Recruiting
Research Site
Foshan, Guangdong
- Recruiting
Research Site
Fuzhou, Fujian
- Recruiting
Research Site
Ganzhou, Jiangxi
- Recruiting
Research Site
Guangzhou, Guangdong
- Not yet recruiting
Research Site
Guangzhou, Guangdong
- Recruiting
Research Site
Guiyang, Guizhou
- Recruiting
Research Site
Hangzhou, Zhejiang
- Recruiting
Research Site
Harbin, Heilongjiang
- Not yet recruiting
Research Site
Hohhot, Inner Mongolia
- Recruiting
Research Site
Huai An, Jiangsu Province
- Recruiting
Research Site
Jiaozuo, Henan Province
- Recruiting
Research Site
Jinan, Shandong Province
- Recruiting
Research Site
Jining, Shandong Province
- Recruiting
Research Site
Jiujiang, Jiangxi
- Recruiting
Research Site
Kunming, Yunnan
- Recruiting
Research Site
Nanchang, Jiangxi
- Recruiting
Research Site
Nanjing, Jiangsu Province
- Recruiting
Research Site
Nanning, Guangxi
- Recruiting
Research Site
Nanping, Fujian
- Recruiting
Research Site
Nantong, Jiangsu Province
- Recruiting
Research Site
Nanyang, Henan Province
- Recruiting
Research Site
Shanghai, Shanghai
- Recruiting
Research Site
Shangqiu, Henan Province
- Recruiting
Research Site
Shantou, Guangdong
- Recruiting
Research Site
Shaoxing, Zhejiang
- Not yet recruiting
Research Site
Shenyang, Liaoning
- Recruiting
Research Site
Shenzhen, Guangdong
- Recruiting
Research Site
Shijiazhuang, Hebei
- Not yet recruiting
Research Site
Shijiazhuang, Hebei
- Recruiting
Research Site
Suzhou, Jiangsu Province
- Recruiting
Research Site
Taiyuan, Shanxi
- Recruiting
Research Site
Taizhou, Jiangsu
- Recruiting
Research Site
Tianjin, Tianjin
- Recruiting
Research Site
Tonglu County, Zhejiang
- Recruiting
Research Site
Urumqi, Xinjiang
- Recruiting
Research Site
Weifang, Shandong Province
- Recruiting
Research Site
Wuhan, Hubei
- Recruiting
Research Site
XI An, Shaanxi Province
- Recruiting
Research Site
Xiamen, Fujian
- Recruiting
Research Site
Xiangyang, Hubei
- Recruiting
Research Site
Xiantao, Hubei
- Recruiting
Research Site
Xuancheng, Anhui
- Recruiting
Research Site
Yinchuan, Ningxia Hui Autonomous Region
- Recruiting
Research Site
Yiwu,Zhejiang
- Recruiting
Research Site
Zhangzhou, Fujian
- Recruiting
Research Site
Zhenjiang, Jiangsu Province
- Recruiting
Research Site
Zhoushan, Zhejiang
- Recruiting
Research Site
Zhuji, Zhejiang
- Recruiting
Research Site
Zibo, Shandong Province
About this study
Official title: A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Read the detailed description
To ensure a nationally representative cohort, a total of approximately 3000 participants will be enrolled from around 80 sites strategically selected from various geographic regions in China. The sites will include a mix of top-tier tertiary hospitals, regional medical centers, and representative secondary hospitals to accurately reflect real-world clinical practice at different levels of care. All enrolled participants will be followed up to 96 weeks according to the data collection schedule to assess long-term clinical outcomes. Investigators will obtain an informed consent from participants before screening. The CKD participants will only be considered enrolled in the study after providing written informed consent, followed by the assignment of a unique subject identifier. The data will be collected from medical records by the investigator and entered in a cloud-based electronic case report form (eCRF) using electronic data capture (EDC) system. The EDC system is a software tool designed to ensure quality assurance and facilitate data capture during the study. The data will be extracted from established medical records or other documents of the patients and transcribed to the EDC system.
- Conditions
- Chronic Kidney Disease
- Medical subject headings
- Renal Insufficiency, Chronic
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively
To determine the prevalence of HP, HF, HTN, and HK among patients with CKD
Measured: baseline
Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)
To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients with HK
To describe HK outcomes of HK recurrence for all CKD patients with HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients with HK
To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients with HK
To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of Percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of Percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of Proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of Proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
To describe the clinical indicators of Proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients with HP and HTN
To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Measured: Week 0 to week 96
Clinical indicators for CKD patients with HP and HTN
To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Measured: Week 0 to week 96
Clinical indicators for CKD patients with HP and HTN
To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN.
Measured: Week 0 to week 96
Clinical indicators for CKD patients with HF
To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the additional clinical composite outcome of eGFR decline ≥40% for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the additional clinical composite outcome of ESRD for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the additional clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the additional clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the renal outcome of ≥40% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
To describe the HK outcome of new-onset HK for all CKD patients and subgroups with HP, HF, HTN, or HK.
Measured: Week 0 to week 96
Clinical indicators for CKD patients with HF
To describe the clinical indicators of Change of BNP from baseline over time in patients with CKD with HF.
Measured: Week 0 to week 96
Secondary outcomes (62)
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of eGFR slope between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
The HCRU among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
To describe healthcare resource utilization (HCRU) among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicators eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Composite outcome of eGFR decline ≥50% between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of Change in eGFR from baseline over time between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of percent change in UACR from baseline over time between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of percent change in UPCR from baseline over time between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of percent change in UPER from baseline over time between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical indicators of proportion of patients achieving proteinuria control target over time between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
To compare the clinical indicators of Change in systolic BP from baseline over time between CKD patients with or without HP, HTN
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
To compare the clinical indicators of change in diastolic BP from baseline over time between CKD patients with or without HP, HTN
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
To compare the clinical indicators of proportion of patients achieving BP control target over time between CKD patients with or without HP, HTN
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HF
To compare the clinical indicators of Change of NT-proBNP from baseline over time between CKD patients with or without HF
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of change in systolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of change in diastolic BP from baseline over time in patients with CKD overall, and in subgroups with HP,HTN
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
To identify the factors associated with the clinical indicator of Proportion of patients achieving BP control target over time in patients with CKD overall, and in subgroups with HP,HTN
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF
To identify the factors associated with the clinical indicator of change of NT-proBNP from baseline over time in patients with CKD overall, and in subgroups with HF
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the composite outcome of eGFR decline ≥50% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the composite outcome of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the composite outcome of renal death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the composite outcome of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the renal outcomes of ≥50% eGFR decline from baseline in patients with CKD overall, and in subgroups with HP,HTN
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the renal outcomes of ESRD in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the renal outcomes of RRT in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the renal outcomes of CKD stage progression in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with renal-related death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with CV outcomes of MACE in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with CV outcomes of HF in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with CV outcomes of CV death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with CV outcomes of all-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with CV outcomes of all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
To identify the factors associated with HK outcomes of HK recurrence in patients with CKD overall, and in subgroups with HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
To identify the factors associated with HK outcomes of severe HK requiring hospitalisation in patients with CKD overall, and in subgroups with HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
To identify the factors associated with HK outcomes of severe HK requiring emergency-department visits in patients with CKD overall, and in subgroups with HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of composite outcome of ESRD between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of composite outcome of renal death between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of composite outcome of CV death between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Renal outcomes of ≥50% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Renal outcomes of ESRD between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Renal outcomes of RRT between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of CKD stage progression between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Renal-related death between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of CV outcomes of MACE between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of CV outcomes of hHF between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of All-cause death between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of All-cause hospitalization between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HK
To compare the clinical outcomes of HK recurrence between CKD patients with or without HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HK
To compare the clinical outcomes of Severe HK requiring hospitalisation between CKD patients with or without HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HK
To compare the clinical outcomes of Severe HK requiring emergency-department visits between CKD patients with or without HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with All-cause death in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with all-cause hospitalization in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HF
To compare the clinical indicators of Change of BNP from baseline over time between CKD patients with or without HF
Measured: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF
To identify the factors associated with the clinical indicator of change of BNP from baseline over time in patients with CKD overall, and in subgroups with HF
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with the composite outcome of eGFR decline ≥40% in patients with CKD overall, and in subgroups with HP, HF, HTN, and HK
Measured: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
To identify the factors associated with HK outcomes of new-onset HK in patients with CKD overall, and in subgroups with HP, HF, HTN
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of Renal outcomes of ≥40% eGFR decline from baseline between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
To compare the clinical outcomes of HK outcome for new-onset HK between CKD patients with or without HP, HF, HTN, HK
Measured: Week 0 to week 96
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2026
- Study start27 Feb 2026
- Primary completion30 Dec 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 96 Weeks
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Xiao Qiang Ding, Principal investigator, Zhongshan Hospital Affiliated with Fudan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07481526
- Sponsor's protocol ID
- D4327R00004
- Status last verified
- Aug 2026
- First submitted
- 13 Feb 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter Real-World Registry of Characteristics, Treatment Strategies, and Clinical Outcomes in Chinese Adults With Chronic Kidney Disease
- ClinicalTrials.gov ID
- NCT07481526
- Acronym / sponsor ID
- D4327R00004
- Conditions
- Chronic Kidney Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 27 Feb 2026 (actual)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 19 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Detailed description
To ensure a nationally representative cohort, a total of approximately 3000 participants will be enrolled from around 80 sites strategically selected from various geographic regions in China. The sites will include a mix of top-tier tertiary hospitals, regional medical centers, and representative secondary hospitals to accurately reflect real-world clinical practice at different levels of care. All enrolled participants will be followed up to 96 weeks according to the data collection schedule to assess long-term clinical outcomes. Investigators will obtain an informed consent from participants before screening. The CKD participants will only be considered enrolled in the study after providing written informed consent, followed by the assignment of a unique subject identifier. The data will be collected from medical records by the investigator and entered in a cloud-based electronic case report form (eCRF) using electronic data capture (EDC) system. The EDC system is a software tool designed to ensure quality assurance and facilitate data capture during the study. The data will be extracted from established medical records or other documents of the patients and transcribed to the EDC system.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 96 Weeks
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adult CKD patients who meet the eligibility criteria
Key inclusion criteria (5 listed)
- Male or female patients aged ≥18 years.
- Willing and able to provide written informed consent to participate in the study.
- Confirmed CKD diagnosis at enrolment, defined by at least one of the following:
Key exclusion criteria (5 listed)
- Having a life-threatening comorbidity with life expectancy < 2 years.
- Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
- Pregnant or breastfeeding women.
- Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
- Presenting with ESRD, RRT, acute kidney injury (AKI), acute kidney disease (i.e., kidney injury or a decline in renal function persisting for ≤3 months) as a primary disease condition at enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively
Time frame: baseline
To determine the prevalence of HP, HF, HTN, and HK among patients with CKD
Adoption rate of medications (e.g., Endothelin receptor antagonists [ERA], MRA, RASi, SGLT2i)
Time frame: Week 0 to week 96
To describe the treatment patterns in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of eGFR slope in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the clinical composite outcome of eGFR decline ≥50% for CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the clinical composite outcome of End-stage renal disease(ESRD) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of ≥50% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of ESRD from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of RRT(renal replacement therapy) from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of CKD stage progression for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of Renal-related death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the CV outcome of MACE(major adverse cardiovascular events) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the CV outcome of HF for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the CV outcome of CV death (included in the composite of renal or CV death) for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe all-cause death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe all-cause hospitalization for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients with HK
Time frame: Week 0 to week 96
To describe HK outcomes of HK recurrence for all CKD patients with HK.
Clinical outcomes of CKD patients with HK
Time frame: Week 0 to week 96
To describe HK outcomes of Severe HK requiring hospitalisation for all CKD patients with HK.
Clinical outcomes of CKD patients with HK
Time frame: Week 0 to week 96
To describe HK outcomes of Severe HK requiring emergency-department visits for all CKD patients with HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of change in eGFR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of percent change in UACR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of Percent change in UPCR from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of Percent change in UPER from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of Proportion of patients achieving proteinuria control target over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of Proportion of patients achieving UPCR < 1000 mg/g and ≥ 30% reduction from baseline over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
To describe the clinical indicators of Proportion of patients achieving UPER <1000 mg/24h with ≥30% reduction over time in patients with CKD overall, and in subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients with HP and HTN
Time frame: Week 0 to week 96
To describe the clinical indicators of Change in systolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HP and HTN
Time frame: Week 0 to week 96
To describe the clinical indicators of Change in diastolic BP from baseline over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HP and HTN
Time frame: Week 0 to week 96
To describe the clinical indicators of Proportion of patients achieving BP control target over time in patients with CKD and subgroups of HP and HTN.
Clinical indicators for CKD patients with HF
Time frame: Week 0 to week 96
To describe the clinical indicators of Change of NT-proBNP from baseline over time in patients with CKD with HF.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the additional clinical composite outcome of eGFR decline ≥40% for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the additional clinical composite outcome of ESRD for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the additional clinical composite outcome of renal death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the additional clinical composite outcome of CV death for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the renal outcome of ≥40% eGFR decline from baseline for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical outcomes of CKD patients and CKD patients with HP,HF,HTN,or HK
Time frame: Week 0 to week 96
To describe the HK outcome of new-onset HK for all CKD patients and subgroups with HP, HF, HTN, or HK.
Clinical indicators for CKD patients with HF
Time frame: Week 0 to week 96
To describe the clinical indicators of Change of BNP from baseline over time in patients with CKD with HF.
62 secondary outcomes
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
The HCRU among patients with CKD overall, and in subgroups with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HP and HTN
Time frame: Week 0 to week 96
Clinical indicators of CKD patients and CKD patients with HF
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups
Time frame: Week 0 to week 96
The factors associated with the clinical indicators in patients with CKD overall, and in subgroups of HF
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HP, HF, HTN, and HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
Time frame: Week 0 to week 96
The factors associated with the clinical outcomes in patients with CKD overall, and in subgroups of HK
Time frame: Week 0 to week 96
Clinical outcomes of CKD patients and CKD patients with HP, HF, HTN, or HK
Time frame: Week 0 to week 96
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for Chronic Kidney Disease
RecruitingPhase 2
Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD
Chronic Kidney Disease
Not yet recruiting
Combined Versus Multicomponent Training in People With Chronic Kidney Disease Stages 3a and 3b
Chronic Kidney Disease Stage 3A, Chronic Kidney Disease Stage 3B
Recruiting
Dry Weight Reduction Intervention Via Extra Ultrafiltration
Fluid Accumulation, Blood Pressure Management
Not yet recruiting
Cycling During Dialysis: A Feasibility and Safety Study
Hemodialysis, Kidney Disease, End-Stage
Active, not recruitingPhase 4
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
Chronic Kidney Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
Xiao Qiang Ding principal investigator
Zhongshan Hospital Affiliated with Fudan University
59 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Kidney Disease, run by AstraZeneca at 59 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 59 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of CKD patients with HP, HF, HTN, and HK at baseline, respectively (time frame: baseline). The study lists 38 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.